Abstract
Legumain (LGMN; EC: 3.4.22.34), an asparaginyl endopeptidase (AEP) or asparaginyl carboxypeptidase (ACP), is a member of the C13 family of cysteine proteases. Elevated expression of LGMN is reported not only in the tumor cells of breast, prostate, and liver but also in the macrophages of the tumor microenvironment. Hence, LGMN is considered as a key protein involved in the regulation of tumor angiogenesis, invasion, and metastasis. Targeting LGMN using siRNA or pharmacological agents and peptides was reported to reduce cancer cell proliferation in vitro and shrink tumor size in vivo. Moreover, expression of LGMN is significantly low in normal cells compared to tumor cells or tumor-associated macrophages (TAMs); hence, legumain can be used as a marker for tumor recognition and targeting. Therefore, approaches inhibiting LGMN expression or activity are more viable, less toxic, and help in developing the targeted therapeutics. However, to date, LGMN targeting strategies have not been well reported. In this review, an attempt was made to summarize articles pertaining to LGMN (a) structure and activity; (b) oncogenic nature; (c) pharmacological inhibitors; and (d) targeting approaches that inhibit tumor growth. Furthermore, a list of existing gaps in LGMN research is highlighted, which needs additional studies.
Keywords: Legumain, cancers, TAMs, metastasis, targeted therapies, DNA vaccines, miRNAs.
Current Pharmaceutical Design
Title:An Overview of Targeting Legumain for Inhibiting Cancers
Volume: 27 Issue: 31
Author(s): Bandi D. Reddy, Narasimha M. Beeraka, CH. M. Kumari Chitturi and SubbaRao V. Madhunapantula*
Affiliation:
- Center of Excellence in Molecular Biology and Regenerative Medicine, Department of Biochemistry, (A DST-FIST Sponsored Department), JSS Medical College, JSS Academy of Higher Education & Research, Mysore - 570 015, Karnataka,India
Keywords: Legumain, cancers, TAMs, metastasis, targeted therapies, DNA vaccines, miRNAs.
Abstract: Legumain (LGMN; EC: 3.4.22.34), an asparaginyl endopeptidase (AEP) or asparaginyl carboxypeptidase (ACP), is a member of the C13 family of cysteine proteases. Elevated expression of LGMN is reported not only in the tumor cells of breast, prostate, and liver but also in the macrophages of the tumor microenvironment. Hence, LGMN is considered as a key protein involved in the regulation of tumor angiogenesis, invasion, and metastasis. Targeting LGMN using siRNA or pharmacological agents and peptides was reported to reduce cancer cell proliferation in vitro and shrink tumor size in vivo. Moreover, expression of LGMN is significantly low in normal cells compared to tumor cells or tumor-associated macrophages (TAMs); hence, legumain can be used as a marker for tumor recognition and targeting. Therefore, approaches inhibiting LGMN expression or activity are more viable, less toxic, and help in developing the targeted therapeutics. However, to date, LGMN targeting strategies have not been well reported. In this review, an attempt was made to summarize articles pertaining to LGMN (a) structure and activity; (b) oncogenic nature; (c) pharmacological inhibitors; and (d) targeting approaches that inhibit tumor growth. Furthermore, a list of existing gaps in LGMN research is highlighted, which needs additional studies.
Export Options
About this article
Cite this article as:
Reddy D. Bandi , Beeraka M. Narasimha, Chitturi Kumari CH. M. and Madhunapantula V. SubbaRao*, An Overview of Targeting Legumain for Inhibiting Cancers, Current Pharmaceutical Design 2021; 27 (31) . https://dx.doi.org/10.2174/1381612826666201125111625
DOI https://dx.doi.org/10.2174/1381612826666201125111625 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine
Current Pharmaceutical Design Immunosensors in Early Cancer Diagnostics: From Individual to Multiple Biomarker Assays
Current Medicinal Chemistry Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Clinical Cancer Drugs The Antioxidant Activity of Coumarins and Flavonoids
Mini-Reviews in Medicinal Chemistry Novel Non-Steroidal Anti-Inflammatory Drugs: What we have Learned from Animal Studies
Current Drug Targets - Inflammation & Allergy Multiple Sclerosis: Current and Future Treatment Options
Endocrine, Metabolic & Immune Disorders - Drug Targets TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy Photodynamic Therapy For Non-Melanoma Skin Cancers
Current Cancer Therapy Reviews New Optical Molecular Imaging Systems
Current Pharmaceutical Biotechnology Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: “miRNA and Cancer; Computational and Experimental Approaches”)
Current Pharmaceutical Biotechnology Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention
Current Pharmaceutical Design Polymer-Based Gene Delivery: A Current Review on the Uptake and Intracellular Trafficking of Polyplexes
Current Gene Therapy Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design